Delivery Order SPE2DR25D2003-SPE2DR26FQ98V
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,792.62 to AmerisourceBergen Drug Corp for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens. The award, issued on August 14, 2025, with an ultimate completion date of August 15, 2025, represents a firm fixed price delivery order with no set-aside designation. The product will be delivered to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,027.62 to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with an ultimate completion date of September 15, 2025. This is a firm fixed-price delivery order with no set-aside designation, meaning it was competitively awarded. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,729.10 to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with an ultimate completion date of November 5, 2025. This is a firm fixed-price delivery order with no set-aside designation, indicating competitive award. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $8,697.26 to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL FlexPen 3mL insulin pens. This non-set-aside, firm fixed-price delivery order was awarded on December 3, 2025, with an ultimate completion date of December 4, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order valued at $10,646.49 to AmerisourceBergen Drug Corp for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens. The contract, which was not set-aside and was competitively awarded, was executed on June 17, 2025, with an ultimate completion date of June 18, 2025. Performance will take place at the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order falls under AmerisourceBergen's...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on September 17, 2025, for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with a ceiling value of $4,966.59. This is a firm fixed-price delivery order with no set-aside designation, performed at the contractor's corporate office location in Conshohocken, Pennsylvania, and scheduled for completion by September 18, 2025. The order is issued under AmerisourceBergen's Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order valued at $1,265.40 to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with an ultimate completion date of September 15, 2025. The contract represents a firm fixed price, non-set-aside delivery order executed on September 12, 2025, with performance to be fulfilled at AmerisourceBergen's Conshohocken, Pennsylvania facility. This award is a child contract under AmerisourceBergen's substantial $999,999,999...
- The Defense Logistics Agency (DLA) awarded a $1,047.95 delivery order to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with a completion date of September 29, 2025. This competitively awarded, firm fixed-price contract contains no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC)...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,405.80 to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL FlexPen 3mL insulin pens. This non-competitive, firm fixed-price delivery order was awarded on April 24, 2025, with an ultimate completion date of April 25, 2025. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order represents a child contract executed under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $15,204.12 to AmerisourceBergen Drug Corp for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens. Issued on August 27, 2025, this firm fixed price delivery order is scheduled for completion by August 28, 2025, with performance taking place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The award represents a non-competitive delivery order issued under a larger contract vehicle and reflects the...
- SPE2DR25D2003Indefinite Delivery Contract
- SPE2DR25D2003-SPE2DR26FQ98VDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,830.66 to AmerisourceBergen Drug Corp for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens. The award was made on November 24, 2025, under a firm fixed-price contract type with an ultimate completion date of November 25, 2025. This delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. As a child contract, this delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999.99 million through December 2026, which serves as the comprehensive global pharmaceutical support vehicle for military healthcare programs worldwide. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and critical vendor for federal medical procurement, particularly supporting military and veteran healthcare systems. The company's extensive federal contract portfolio with the DLA encompasses a broad range of pharmaceutical products including diabetes medications, neurological treatments, pain management drugs, antibiotics, vaccines, and specialized medical supplies. This delivery order for insulin reflects the company's ongoing role in supplying essential pharmaceutical products to support the Defense Health Agency and other federal healthcare customers through competitively awarded, firm fixed-price transactions.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.8k | 11/23/25 |